Though a randomized study suggested the benefit of in vivo T-cell depletion (TCD) as Graft versus Host Disease (GvHD) prophylaxis in matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT) its use remains controversial. Here we report our single center experience of the use of alemtuzumab in MSD.

Poster author: Dr Liga 
Participants:  D. Tsokanas , E. Sagiadinou , E. Triantafyllou , K. Valera , A. Christopoulou , V. Zacharioudaki , A. Spyridonidis